Business
AbbVie Completes Acquisition of Capstan Therapeutics
AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Capstan Therapeutics. With the completion of the acquisition, Capstan is now a part of AbbVie.
About this update from Abbvie Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Acquisition adds a potential first-in-class in vivo targeted lipid nanoparticle (tLNP) anti-CD19 CAR-T therapy candidate for B cell-mediated autoimmune diseases as well as a proprietary tLNP platform designed to deliver RNA payloads, such as mRNA, capable of engineering specific cell types in vivo","length":303,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":303,"olType":false},{"type":"text","content":"NORTH CHICAGO, Ill., Aug. 19, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Capstan Therapeutics. With the completion of the acquisition, Capstan is now a part of AbbVie.","length":222,"tagName":"p"},{"type":"text","content":"Capstan's lead asset CPTX2309, currently in Phase 1 for the treatment of B cell-mediated autoimmune diseases, is a tLNP that generates CD19-specific, CD8+ in vivo CAR-T cells. The CAR-T cells are designed to achieve rapid and deep B cell depletion with the aim of achieving durable, drug-free remission. This can be accomplished without the need for lymphodepleting chemotherapy, while also avoiding other challenges associated with conventional ex vivo CAR-T therapies.","length":474,"tagName":"p"},{"type":"text","content":""With the acquisition now complete, we are excited to work together with the talented team at Capstan to advance our mission of transforming patient care," said Jonathon Sedgwick, Ph.D., senior vice president and global head of discovery research, AbbVie. "The addition of CPTX2309 and Capstan's tLNP platform strengthens our ability to deliver new treatments aimed at resetting the immune system and enables application of Capstan's proprietary technology more broadly for in vivo programming of cells."","length":532,"tagName":"p"},{"type":"text","content":"For additional background on the acquisition, please read the press release announcing the definitive agreement under which AbbVie will acquire Capstan here.","length":157,"tagName":"p"},{"type":"text","content":"About AbbVie","length":12,"tagName":"p"},{"type":"text","content":"AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across...